Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
May 25, 2021 DOI: 10.64239/pi-qt2702 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Topics | Esketamine |
|---|---|
| Key points | Esketamine is more likely than venlafaxine to cause suicidal ideation, induce mania, and produce euphoric mood, suggesting abuse potential. |
Abstract
Esketamine appears more likely than venlafaxine to cause suicidal ideation. Induction of mania was more common than with venlafaxine. Induction of euphoric mood suggests abuse potential. Caution is warranted.